Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: Do onabotulinum toxin-A injections improve sexual function?

Basit Öğe Kaydı
dc.contributor.authorTopçuoglu, Murat
dc.contributor.authorKaraburun, Murat Can
dc.contributor.authorİbiş, Arif Halil
dc.contributor.authorGökçe, Mehmet İlker
dc.contributor.authorSüer, Evren
dc.contributor.authorGülpınar, Ömer
dc.date.accessioned2026-01-24T12:20:44Z
dc.date.available2026-01-24T12:20:44Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractIntroduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) has a negative impact on female sexual function. We aimed to evaluate the effect of intravesical botulinum toxin-A (BTX-A) injection on the improvement of sexual dysfunction and urinary symptoms using the multi-domain female sexual function Index (FSFI), interstitial cystitis symptom index (ICSI), and interstitial cystitis problem index (ICPI). Material and Method: The data of the 23 patients (study group) who received intravesical BTX-A with the diagnosis of IC/BPS were reviewed. Twenty-three age-matched healthy, sexually active women were determined as the control group. Patients received 100 U BTX-A submucosally injections, including the trigone. One hundred units of BTX-A were diluted to 20 cc 0.9% saline, and 1 cc was then applied submucosally on 20 different points of the bladder wall (5 U/1 mL per site). The study group was asked to fill out FSFI, ICSI, and ICPI, as well as the visual analog scale (VAS) and bladder diary before and 3 months after the treatment. Patients in the control group completed the same questionnaires once. The pre- and post-treatment questionnaire scores were compared in the study group. The study group's data were also compared to the control group. Results: Compared to the pretreatment period, the study group showed statistically significant improvement in the total FSFI score and each domain of the FSFI after BTX-A injection. The mean total FSFI score and three domains of FSFI (desire, lubrication, pain) reached to the score of the control group following BTX-A injection. Statistically significant improvements were also shown in scores of ICSI, ICPI, and VAS. (p < 0.05). Conclusion: IC/BPS is associated with a very high incidence of sexual dysfunction. Intravesical BTX-A injection may provide significant improvement in sexual dysfunction in women with IC/BPS. © 2023 Wiley Periodicals LLC.
dc.identifier.doi10.1002/nau.25139
dc.identifier.endpage614
dc.identifier.issn0733-2467
dc.identifier.issue3
dc.identifier.pmid36708358
dc.identifier.scopus2-s2.0-85147298722
dc.identifier.scopusqualityQ2
dc.identifier.startpage607
dc.identifier.urihttps://doi.org/10.1002/nau.25139
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4543
dc.identifier.volume42
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofNeurourology and Urodynamics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260121
dc.subjectbladder pain syndrome
dc.subjectbotulinum toxin
dc.subjectinterstitial cystitis
dc.subjectsexual dysfunciton
dc.subjectwomen
dc.titleSexual dysfunction in women with interstitial cystitis/bladder pain syndrome: Do onabotulinum toxin-A injections improve sexual function?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu